arrow_back Trending Legislation
Share share

Alpha-1 Antitrypsin Deficiency Home Treatment: New Medicare Coverage

This act aims to improve access to home treatment for Alpha-1 Antitrypsin Deficiency for individuals covered by Medicare. It means that the costs of intravenous administration kits and nursing services related to this treatment will be covered, potentially reducing financial burden and improving quality of life for patients.
Key points
Medicare Part B will cover Alpha-1 Antitrypsin Deficiency treatment (augmentation therapy) provided at home by qualified suppliers.
The act ensures coverage for intravenous administration kits and up to 2 hours of nursing services for home therapy administration.
These changes will take effect on January 1, 2025, allowing time for preparation for the new rules.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
John W. Walsh Alpha-1 Home Infusion Act of 2023
Print number: HR 4438
Sponsor: Rep. Salazar, Maria Elvira [R-FL-27]
Process start date: 2023-06-30
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Alpha-1 Antitrypsin Deficiency Home Treatment: New Medicare Coverage

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 4438.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-06-30.

What are the main provisions?

Key points include:

  • Medicare Part B will cover Alpha-1 Antitrypsin Deficiency treatment (augmentation therapy) provided at home by qualified suppliers.
  • The act ensures coverage for intravenous administration kits and up to 2 hours of nursing services for home therapy administration.
  • These changes will take effect on January 1, 2025, allowing time for preparation for the new rules.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Salazar, Maria Elvira [R-FL-27].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Analysis and Potential Impact of HR 4438

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Benefits